ArticleScientific reports2016
Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Maternal Blood as a Window to the Fetal Heart: Novel Biomarkers for Early Detection of Septal Defects.Biomedicines · 2026Review
- Association of obstetrics and foetal ultrasound parameters with maternal serum Lamin A: A teaching institution-based cross-sectional study.Journal of family medicine and primary care · 2026Article
- A novel tsRNA signature -tRF-58:76-Tyr-GTA-2-M3 as potential biomarker and therapeutic target for duodenal atresia.Cell biology and toxicology · 2025Article
- Performance of ultrasound in detecting fetal hypospadias during pregnancy: a pooled analysis.EClinicalMedicine · 2025Article
- Article
- Looking at a baby's heart through the lens of the mother's blood.EMBO molecular medicine · 2023Article
- The 'omics of obesity in B-cell acute lymphoblastic leukemia.Journal of the National Cancer Institute. Monographs · 2023Article
- Maternal serum CFHR4 protein as a potential non-invasive marker of ventricular septal defects in offspring: evidence from a comparative proteomics study.Clinical proteomics · 2022Article
- Nanostructures in non-invasive prenatal genetic screening.Biomedical engineering letters · 2022Review
- Label-Free Physical Techniques and Methodologies for Proteins Detection in Microfluidic Biosensor Structures.Biomedicines · 2022Review
- HBFP: a new repository for human body fluid proteome.Database : the journal of biological databases and curation · 2021Article
- Human body-fluid proteome: quantitative profiling and computational prediction.Briefings in bioinformatics · 2021Review
- Molecular Diagnostics and In Utero Therapeutics for Orofacial Clefts.Journal of dental research · 2020Review
- Prenatal maternal biomarkers for the early diagnosis of congenital malformations: A review.Pediatric research · 2019Review
- A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients.Molecular medicine reports · 2017Article
- Proteomic profile of the Bradysia odoriphaga in response to the microbial secondary metabolite benzothiazole.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital heart defects (CHDs) are the most common group of major birth defects. Presently there are no clinically used biomarkers for prenatally detecting CHDs. Here, we performed a comprehensive maternal serum proteomics assessment, combined with immunoassays, for the discovery of non-invasive biomarkers for prenatal diagnosis of CHDs. A total of 370 women were included in this study. An isobaric tagging for relative and absolute quantification (iTRAQ) proteomic approach was used first to compare protein profiles in pooled serum collected from women who had CHD-possessing or normal fetuses, and 47 proteins displayed significant differential expressions. Targeted verifications were performed on 11 proteins using multiple reaction monitoring mass spectrometry (MRM-MS), and the resultant candidate biomarkers were then further validated using ELISA analysis. Finally, we identified a biomarker panel composed of 4 cytoskeletal proteins capable of differentiating CHD-pregnancies from normal ones [with an area under the receiver operating characteristic curve (AUC) of 0.938, P < 0.0001]. The discovery of cytoskeletal protein changes in maternal serum not only could help us in prenatal diagnosis of CHDs, but also may shed new light on CHD embryogenesis studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.